Dataset Open Access

Large-scale purification of Q23 HTT from Sf9 2019/09/30

Harding, Rachel; Hutchinson, Ashley; Seitova, Alma; Arrowsmith, Cheryl; Edwards, Aled

Dublin Core Export

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="" xmlns:oai_dc="" xmlns:xsi="" xsi:schemaLocation="">
  <dc:creator>Harding, Rachel</dc:creator>
  <dc:creator>Hutchinson, Ashley</dc:creator>
  <dc:creator>Seitova, Alma</dc:creator>
  <dc:creator>Arrowsmith, Cheryl</dc:creator>
  <dc:creator>Edwards, Aled</dc:creator>
  <dc:description>Project: Biophysical investigation of purified HTT protein samples

Experiment: Large-scale purification of Q23 HTT from Sf9 

Date completed:­ 2019/09/30

Rationale: HTT samples are to be purified from different systems for subsequent biophysical and structural studies. </dc:description>
  <dc:description>Dr. Harding is the recipient of the Huntington's Disease Society of America Berman Topper Career Development Fellowship which funds and supports this research, in addition to generous funding from the CHDI Foundation and the Huntington Society of Canada. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.</dc:description>
  <dc:subject>Huntington's disease</dc:subject>
  <dc:subject>protein purification</dc:subject>
  <dc:title>Large-scale purification of Q23 HTT from Sf9 2019/09/30</dc:title>
All versions This version
Views 7171
Downloads 2424
Data volume 4.6 MB4.6 MB
Unique views 6464
Unique downloads 2121


Cite as